Set of reagents for determining the activity of fibrin-stabilizing factor (factor XIII) (Factor XIII Test) according to TU 9398-013-05595541-2007 Designed for investigating the activity of factor XIII in human blood plasma using a manual method.
Factor XIII completes the process of forming a fibrin clot by forming stable peptide bonds between fibrin monomers. A decrease in the level of factor XIII is observed in patients with congenital factor deficiency, as well as as a secondary syndrome in severe liver damage, sepsis, radiation sickness, after major surgeries. The clinical picture of factor XIII deficiency manifests as a severe hemorrhagic syndrome.
Principle of the method: The determination of factor XIII activity is based on assessing the lysis of a fibrin clot containing varying amounts of the investigated factor XIII in 5% monochloroacetic acid.
Composition of the kit:
One kit is intended for conducting 40 determinations with a consumption of 0.1 ml of thrombin-calcium mixture per analysis.
Normal and pathological values of factor XIII activity in the blood plasma of patients should be controlled using Control Plasma, code KM-2.
Interpretation of results: In the normal plasma of healthy individuals, the level of factor XIII activity is 60-150%. A decrease in the level of factor XIII is observed in patients with congenital deficiency, as well as as a secondary syndrome in severe liver damage, sepsis, radiation sickness, after major surgeries. The clinical picture of factor XIII deficiency manifests as a severe hemorrhagic syndrome, with bleeding duration reaching 12-36 hours.
